drugset / Trial / NCT00083889

SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma

NCT00083889

Phase 3 Completed 750 enrolled Pfizer
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to test whether SU011248 has activity and is safe compared to interferon-alfa as first-line therapy in patients with metastatic renal cell carcinoma (RCC).

Timeline

Start
2004-08
Primary completion
2008-09
Completion
2008-09

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Sunitinib Small molecule 50 mg Oral
Comparator interferon alfa Protein / enzyme biologic 9e+06 iu Subcutaneous

Indications